<DOC>
	<DOCNO>NCT00591136</DOCNO>
	<brief_summary>Dose-finding pharmacokinetic trial orally administer Indibulin patient solid tumor .</brief_summary>
	<brief_title>Phase I Study Indibulin Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Male female patient , &gt; = 18 year age . Histologically/cytologically proven solid malignant tumor , standard treatment proven efficacy longer available . Performance status 02 ECOG/WHO . Life expectancy &gt; 3 month . Able willing undergo blood sample pharmacokinetics . Written informed consent . Exclusion Criteria Safety concern : Any noncompensated uncontrolled nonmalignant condition , , symptomatic heart failure , active tuberculosis chronic active infection . History allergic reaction one ingredients trial medication . Clinically relevant abnormality organ function evidence follow pa¬ra¬meters : White blood cell count : &lt; 3.0 x 109/l ANC : &lt; 1.5 x 109/l Thrombocytes : &lt; 100 x 109/l Hemoglobin &lt; 6.0 mM Bilirubin ( total ) : &gt; 1.5 time upper limit normal range ASAT , ALAT : &gt; 2.5 time upper limit normal range unless related metastasis case &gt; 5 time upper normal limit allow Creatinine ( serum ) &gt; 135 µmol/l ( &gt; 1.5 mg/100ml ) OR Creatinine clearance : &lt; 50 ml/min ( calculate accord modify Cockcroft Gault ) Breast feeding , pregnancy plan pregnancy . A reliable method contraception must use men woman childbearing potential study 3 month last study drug administration . Lack suitability trial : Concomitant treatment investigational drug exposure another investigational agent within last 4 week prior study specific screening procedure ( period extend patient receive drug know de¬layed toxicity prolong halflife ) . Active peptic ulcer GI condition could alter absorption motility . Chronic use H2antagonists proton pump inhibitor . Any cancer treatment study administer within last 4 week ( 6 week nitrosoureas , mitomycin C , highdose carboplatin extensive radiotherapy ) start study treatment , except irradiation nontarget lesion symptom relief biphosphonate treatment bone metastasis . Clinically symptomatic brain metastasis leptomeningeal disease . Neurological psychiatric disease drug alcohol abuse would interfere patient proper completion protocol assignment . Administrative reason : Anticipated nonavailability study visits/procedures .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>